Current and Future Therapies for Multiple Sclerosis | Zendy

Alireza Minagar | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Current and Future Therapies for Multiple Sclerosis

Author(s) -

Alireza Minagar

Publication year - 2013

Publication title -

scientifica

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.474

H-Index - 21

ISSN - 2090-908X

DOI - 10.1155/2013/249101

Subject(s) - teriflunomide , multiple sclerosis , natalizumab , glatiramer acetate , daclizumab , medicine , alemtuzumab , fingolimod , mitoxantrone , ocrelizumab , relapsing remitting , cladribine , clinical trial , dimethyl fumarate , interferon beta 1a , oncology , rituximab , immunology , interferon beta , chemotherapy , transplantation , tacrolimus , lymphoma

With the introduction of interferon- β 1b in 1993 as the first FDA-approved treatment for multiple sclerosis, the era of treatment of this incurable disease began, and its natural course was permanently changed. Currently, seven different treatments for patients with multiple sclerosis with different mechanisms of action and dissimilar side effect profiles exist. These medications include interferon- β 1a intramuscular (Avonex), interferon- β 1a subcutaneous (Rebif), interferon- β 1b subcutaneous (Betaseron/Extavia), glatiramer acetate (Copaxone), natalizumab (Tysabri), fingolimod (Gilenya), teriflunomide (Aubagio), and mitoxantrone (Novantrone). In addition, a large number of clinical trials are being conducted to assess the safety and efficacy of various experimental agents in patients with multiple sclerosis, including alemtuzumab, dimethyl fumarate, laquinimod, rituximab, daclizumab, and cladribine. In this paper, the author presents a concise and comprehensive review of present and potential treatments for this incurable disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research